Opportunities and Obstacles of Targeted Therapy and Immunotherapy in Small Cell Lung Cancer

The authors review the molecular biology characteristics of small cell lung cancer (SCLC) and discuss the opportunities and obstacles of the current therapy for SCLC patients.
[Journal of Drug Targeting]
Yu, L., Lai, Q., Gou, L., Feng, J., & Yang, J. (2020). Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer. Journal of Drug Targeting, 0(0), 1–11. https://doi.org/10.1080/1061186X.2020.1797050 Cite
Abstract

Continue reading “Opportunities and Obstacles of Targeted Therapy and Immunotherapy in Small Cell Lung Cancer”

Bookmark

No account yet? Register

0
Share

Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells

Scientists identified protein kinase A (PKA) as an active kinase in small cell lung cancer (SCLC). Inhibition of PKA activity genetically, or pharmacologically by activation of the PP2A phosphatase, suppressed SCLC expansion in culture and in vivo.
[Cancer Cell]
Coles, G. L., Cristea, S., Webber, J. T., Levin, R. S., Moss, S. M., He, A., Sangodkar, J., Hwang, Y. C., Arand, J., Drainas, A. P., Mooney, N. A., Demeter, J., Spradlin, J. N., Mauch, B., Le, V., Shue, Y. T., Ko, J. H., Lee, M. C., Kong, C., … Sage, J. (2020). Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell, 0(0). https://doi.org/10.1016/j.ccell.2020.05.003 Cite
AbstractGraphical Abstract

Continue reading “Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells”

Bookmark

No account yet? Register

0
Share
Share